stockrow
Monday 9 November 2026
Export MENS’s income statement to Excel — free account
Jyong Biotech Ltd.
MENS
1.80
0.15
+9.09%
Follow MENS
Alert me
Jyong Biotech Ltd. (MENS) Return on invested capital
Jyong Biotech Ltd.'s return on invested capital over the twelve months to 31 December 2025 was 0.00%. That is in line with the Biotechnology industry median of 0.00% and in line with the Healthcare sector median of 0.00%.
Return on invested capital, annual
Embed this chart
Annual newest first
| Period | Return on invested capital | Change (points) |
|---|---|---|
| FY2025 | 0.00% | 0.00 |
| FY2024 | 0.00% | 0.00 |
| FY2023 | 0.00% | — |
Return on invested capital against peers
| Company | Return on invested capital |
|---|---|
| PDSB PDS Biotechnology Corporation compare | 0.00% |
| MENS Jyong Biotech Ltd. | 0.00% |
| PYPD PolyPid Ltd. compare | 0.00% |
| CHRS Coherus Oncology, Inc. compare | 0.00% |
| YARW Yarrow Bioscience, Inc compare | 0.00% |
| MOLN Molecular Partners AG Sponsored ADR compare | 0.00% |
| SPRB Spruce Biosciences, Inc. compare | 0.00% |
| CMPX Compass Therapeutics, Inc. compare | 0.00% |
| TARA Protara Therapeutics, Inc. compare | −255.1% |
| Biotechnology industry median | 0.00% |
| Healthcare sector median | 0.00% |
| Market median | 0.00% |
What Return on invested capital is
Return on Invested Capital shows how much after-tax operating profit a company earns on the money its lenders and shareholders have put in.
TTM: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) (latest quarter) + Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter) − Cash & Short Term Investments (latest quarter)); Annual: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) + Long Term Debt (Total) + Current Part of Debt − Cash & Short Term Investments)